Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A11911 | Pages: NA | Charts: NA | Tables: NA |
Blood cell analyzer, also known as hematology analyzer, is used in patient and research settings to depict and count blood cells to diagnose disorders. Complex analyzer is used to identify small cells and quantify cell shape to assess unusual blood condition, whereas basic analyzer offers a blood count with a three-section differential white blood cell count. Blood cell analyzer is made up of a number of analytical modules that each have their own set of sample preparation methods. Viruses, anemia, infections, cancer, genetic disorders, and diabetes are just a few of the ailments they can help diagnose. These analyzers are further used by research organizations, hospitals, and clinical testing laboratories. They are specialized computers that determine the presence and count of several types of cellular components in the blood samples.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the blood cell analyzer market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish the Market
In March 2018, Roche launched cobas m 511 integrated hematology analyzer, featuring patented Bloodhound technology, is designed to address the challenges of hematology testing by combining a cell counter, slide maker, stainer, and a digital morphology analyzer into one integrated solution.
In September 2020, Agappe Diagnostics Ltd. introduced the first indigenously developed blood cell counter, Mispa Count X. This hematology analyzer (blood cell counting) has been designed and developed in collaboration with L&T Technology Services Limited.
In March 2021, Sysmex Corporation launching the XS-500, an automated hematology analyzer of its XS-Series.
In January 2018, Abbott launched ALINITY H-SERIES integrated hematology analyzer, combining speed, accuracy, and seamless integration.
Surge in Usage in Blood-related Disorders Treatment
Increase in prevalence of blood clot-related disorders, rise in utilization of these blood cell analyzers in examination settings, rise in demand for minimally invasive procedure drive the growth of blood cell analyzer market.
In addition, increase in healthcare expenditure, collaborations & partnerships between key players to facilitate drug development, rise in R&D activities to improve quality of drugs, launches of novel developed drug in market are some factors that notably contribute toward the market growth of blood cell analyzer market.
Key Benefits of the Report
Questions Answered in the Blood Cell analyzer Market Report
Key Market Segments
Key Market Players